venBio Select Advisor

Latest statistics and disclosures from Avoro Capital Advisors's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are ASND, UTHR, MDGL, ARGX, KRYS, and represent 51.26% of Avoro Capital Advisors's stock portfolio.
  • Added to shares of these 10 stocks: GPCR (+$151M), CNTA (+$141M), QURE (+$48M), MRUS (+$36M), SLNO (+$36M), OCUL (+$33M), RNA (+$26M), ASND (+$26M), ORKA (+$26M), AKRO (+$22M).
  • Started 3 new stock positions in GPCR, TNGX, ORKA.
  • Reduced shares in these 10 stocks: ARGX (-$136M), UTHR (-$62M), BPMC (-$48M), BCRX (-$25M), FOLD (-$23M), ALKS (-$20M), MDGL (-$19M), GLUE (-$17M), MLTX (-$15M), RARE (-$12M).
  • Sold out of its positions in BPMC, GLUE, RARE.
  • Avoro Capital Advisors was a net buyer of stock by $177M.
  • Avoro Capital Advisors has $7.8B in assets under management (AUM), dropping by 36.96%.
  • Central Index Key (CIK): 0001633313

Tip: Access up to 7 years of quarterly data

Positions held by venBio Select Advisor consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Avoro Capital Advisors

Avoro Capital Advisors holds 30 positions in its portfolio as reported in the September 2025 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Ascendis Pharma Sponsored ADR (ASND) 13.0 $1.0B +2% 5.1M 198.81
 View chart
United Therapeutics Corp Common (UTHR) 11.9 $932M -6% 2.2M 419.21
 View chart
Madrigal Pharmaceuticals Common (MDGL) 10.8 $841M -2% 1.8M 458.66
 View chart
Argenx Se Sponsored ADR (ARGX) 9.3 $730M -15% 990k 737.56
 View chart
Krystal Biotech Common (KRYS) 6.3 $490M +4% 2.8M 176.53
 View chart
Arrowhead Pharmaceuticals Common (ARWR) 4.8 $376M +2% 11M 34.49
 View chart
Kymera Therapeutics Common (KYMR) 4.6 $359M -3% 6.4M 56.60
 View chart
Merus N V Common (MRUS) 4.3 $334M +12% 3.5M 94.15
 View chart
Avidity Biosciences Common (RNA) 4.3 $333M +8% 7.6M 43.57
 View chart
Apellis Pharmaceuticals Common (APLS) 3.5 $277M 12M 22.63
 View chart
Centessa Pharmaceuticals Sponsored Adr (CNTA) 3.4 $262M +116% 11M 24.25
 View chart
Uniqure Nv Common (QURE) 3.3 $259M +22% 4.4M 58.37
 View chart
Xenon Pharmaceuticals Common (XENE) 2.8 $217M 5.4M 40.15
 View chart
Akero Therapeutics Common (AKRO) 2.4 $188M +13% 4.0M 47.48
 View chart
Vera Therapeutics Common (VERA) 2.3 $181M 6.2M 29.06
 View chart
Soleno Therapeutics Common (SLNO) 2.2 $174M +25% 2.6M 67.60
 View chart
Structure Therapeutics Sponsored Ads (GPCR) 1.9 $151M NEW 5.4M 28.00
 View chart
Tourmaline Bio Common (TRML) 1.6 $122M 2.6M 47.83
 View chart
Ocular Therapeutix Common (OCUL) 1.5 $120M +38% 10M 11.69
 View chart
Amicus Therapeutics Common (FOLD) 1.5 $118M -16% 15M 7.88
 View chart
89bio Common (ETNB) 1.2 $94M -5% 6.4M 14.70
 View chart
Taysha Gene Therapies Common (TSHA) 0.9 $71M 22M 3.27
 View chart
Alkermes Common (ALKS) 0.9 $67M -22% 2.2M 30.00
 View chart
Oruka Therapeutics Common (ORKA) 0.3 $26M NEW 1.3M 19.23
 View chart
Septerna Common (SEPN) 0.3 $25M +8% 1.3M 18.81
 View chart
Mannkind Corp Common (MNKD) 0.3 $24M -23% 4.5M 5.37
 View chart
Moonlake Immunotherapeutics Class A Ord (MLTX) 0.2 $14M -51% 2.0M 7.17
 View chart
Biocryst Pharmaceuticals Common (BCRX) 0.1 $9.5M -72% 1.3M 7.59
 View chart
Whitehawk Therapeutics Common (WHWK) 0.1 $5.4M 2.8M 1.90
 View chart
Tango Therapeutics Common (TNGX) 0.1 $4.6M NEW 545k 8.40
 View chart

Past Filings by Avoro Capital Advisors

SEC 13F filings are viewable for Avoro Capital Advisors going back to 2014

View all past filings